老年:提早警惕隐匿休克Older adults: occult shock warning
≥65 岁;SBP <110 mmHg以本院规范为准。Age ≥65; SBP <110 mmHg Follow institutional policy.老年创伤高风险识别/分诊提示,不等于单独确诊休克。Older-trauma high-risk triage signal, not a stand-alone shock diagnosis.
≥65岁SBP<110或HR>SBP提示风险;抗凝+头伤即使体征正常也升级评估。以本院规范为准。At least 65 years with SBP below 110 or HR above SBP raises concern; anticoagulated head injury escalates assessment even with apparently normal signs. Follow institutional policy.
低能量伤合并症状、抗凝或灌注异常:提早高级评估。Low-energy injury with symptoms, anticoagulation or poor perfusion: early senior review.
中华医学会相关学组:重伤院前救治共识(2026)Chinese expert consensus on prehospital major trauma (2026) · 国家卫健委:老年髋部骨折诊疗与管理指南(2022年版)NHC geriatric hip fracture care and management guideline (2022)
国内外依据与适用差异Domestic/international scope differences
110阈值源于重伤院前共识;髋部指南仅作国内骨科后续路径入口。The 110 signal comes from prehospital consensus; hip guidance is a domestic orthopedic pathway entry.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
抗凝药:识别后逆转路径Anticoagulants: reversal pathway
危及生命出血:核对药物、末次剂量、INR/肾功能/抗XaLife-threatening bleeding: drug, last dose, INR/renal function/anti-Xa危及生命/不可控出血或紧急高风险手术;由授权团队决策。Life-threatening/uncontrolled bleeding or urgent high-risk surgery; authorized team decisions.
华法林:4F-PCC25–50 IU/kg按INR+维生素K₁5–10 mg缓慢静注;可及4F-PCC优于FFP。达比加群:依达赛珠单抗5 g静注。Xa药:可考虑4F-PCC25–50 IU/kg;ICH按2026条件性推荐优先4F-PCC。以本院规范为准。Warfarin: 4F-PCC 25–50 IU/kg by INR plus vitamin K1 5–10 mg slow IV; available 4F-PCC preferred to FFP. Dabigatran: idarucizumab5 g IV. Xa agents: consider4F-PCC 25–50 IU/kg; 2026 ICH conditional guidance favors4F-PCC. Follow institutional policy.
andexanet美商业销售已停止;欧盟/英国仍可条件获得,权衡获益不确定、血栓和费用。创伤性ICH抗血小板输注尚无统一推荐,不自动常规使用。US andexanet sales have ceased; conditional EU/UK availability requires benefit/thrombosis/cost review. Traumatic antiplatelet-associated ICH has no uniform platelet-transfusion recommendation; do not use automatically.
创伤失血性休克中国急诊专家共识(2023)Chinese emergency consensus on traumatic hemorrhagic shock (2023) · 围术期出凝血管理麻醉专家共识Chinese anesthesia consensus on perioperative bleeding · 欧洲创伤大出血指南第六版(2023)European major bleeding guideline, sixth edition (2023) · FDA:Andexxa安全通讯(2025-12-18)FDA Andexxa safety communication (2025-12-18) · ACEP:DOAC大出血临床政策(2026)ACEP DOAC major-bleeding policy (2026) · NCS/SCCM:抗栓相关颅内出血更新(2026)NCS/SCCM antithrombotic ICH update (2026) · BSH:andexanet立场声明(2026)BSH andexanet position statement (2026)
国内外依据与适用差异Domestic/international scope differences
核对本院PCC三/四因子与标示单位、药品注册和可及性;4F不可及时按血库替代流程,不把FFP等同4F-PCC。与患方共同决策,监测血栓。 andexanet后72 h内血栓风险需重点观察。Check three/four-factor products, units, registration and availability; use local alternatives if4F is unavailable without equating FFP with4F-PCC. Shared decisions and thrombosis monitoring apply. Pay particular attention to early thrombosis within 72 hours after andexanet.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
孕妇创伤:母体与产科并行Pregnancy trauma: maternal/obstetric care
母体优先;子宫左推;Rh DMother first; left uterine displacement; Rh D体位处理:子宫至脐水平/以上;抗D:未致敏RhD阴性腹部/重大创伤,按孕周分支。Positioning: uterus at/above umbilicus; anti-D: unsensitised RhD-negative abdominal/major trauma, by gestation.
未致敏RhD阴性孕妇腹部/重大创伤:72 h内给抗D,先给药不等检测结果。12⁺⁰–19⁺⁶周至少250 IU,无需FMH检测;≥20⁺⁰周至少500 IU,并做FMH(KB或流式)定量决定是否追加。核对本院抗D可及性与剂型。以本院规范为准。Unsensitised RhD-negative woman with abdominal/major trauma: give anti-D within 72 h without waiting for test results. 12+0–19+6 weeks: at least 250 IU, no FMH test needed; ≥20+0 weeks: at least 500 IU plus FMH quantification (Kleihauer or flow cytometry) to decide additional doses. Check local anti-D availability and formulation. Follow institutional policy.
母体不稳定、腹痛/流血或胎心担心:创伤—产科共同升级。Instability, pain/bleeding or fetal concern: trauma/obstetric escalation.
Queensland:妊娠创伤指南Queensland: traumatic injury in pregnancy · 创伤失血性休克中国急诊专家共识(2023)Chinese emergency consensus on traumatic hemorrhagic shock (2023) · BCSH/Qureshi 2014:抗D免疫球蛋白指南BCSH/Qureshi 2014: anti-D immunoglobulin guideline · NHS Highland:妊娠与产后抗D预防路径NHS Highland: anti-D prophylaxis during pregnancy and postnatally
国内外依据与适用差异Domestic/international scope differences
英国BCSH路径:12⁺⁰–19⁺⁶周250 IU、≥20⁺⁰周500 IU并做FMH;Queensland创伤指南另建议RhD阴性≥13⁺⁰周做KB,不可混成同一规则。保留Queensland来源;本院产科/输血科选择一致路径。BCSH出版全文未直接读取,剂量由NHS公开实施路径核对;尚未核实国内等同条款。BCSH pathway: 250 IU at 12+0–19+6 weeks; 500 IU plus FMH at ≥20+0 weeks. Queensland trauma guidance separately recommends KB from 13+0 weeks in RhD-negative women. Keep these pathways distinct and agree one local obstetric/transfusion protocol. BCSH publisher full text was inaccessible; doses were checked against public NHS implementation. No equivalent Chinese clauses were verified.
来源核对日期:2026-10-15;临床审核:进行中Source check: 2026-10-15; clinical review: ongoing
孕妇心停:复苏性分娩Pregnancy arrest: resuscitative delivery
识别心停即准备;目标 ≤5 min 完成;以本院规范为准。Prepare at arrest recognition; goal delivery by ≤5 min Follow institutional policy.宫底达脐或以上(约≥20孕周)、标准复苏无ROSC;受训团队。Fundus at/above umbilicus (approximately at least 20 weeks), no ROSC with standard resuscitation; skilled team.
AHA2025:在心停现场组织产科/麻醉/新生儿团队与复苏性分娩。以本院规范为准。AHA 2025: organize obstetric/anesthetic/neonatal teams and resuscitative delivery at the arrest site. Follow institutional policy.
4 min启动、5 min娩出仍是AHA 2025推荐时间目标;识别心停即呼叫准备,就地实施;超过5 min仍可能获益,不因超时放弃,并行处理创伤可逆原因。以本院规范为准。Four-minute initiation/five-minute birth remains the AHA 2025 timing goal; call/prepare at arrest recognition, perform on site; benefit may remain beyond five minutes, so do not abandon solely for delay; address traumatic causes. Follow institutional policy.
AHA 2025:妊娠心脏骤停AHA 2025: cardiac arrest in pregnancy · Queensland:妊娠创伤指南Queensland: traumatic injury in pregnancy
国内外依据与适用差异Domestic/international scope differences
四/五分钟时点不意味着等待四分钟才呼叫、备器械或备新生儿救援;母体复苏与分娩准备并行。Four/five-minute timing does not justify waiting four minutes to call, prepare equipment or neonatal rescue; maternal resuscitation and delivery preparation are parallel.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
儿童:体重与首轮复苏Children: weight and first aliquot
实测/近期体重;晶体液 10 mL/kg以本院规范为准。Measured/recent weight; crystalloid 10 mL/kg Follow institutional policy.RCH儿童重大创伤,循环不足的首轮等渗液体评估;并行识别出血。RCH major pediatric trauma with poor circulation; assess bleeding in parallel.
疑出血血流动力学受损:小量初始复苏并早用血;RCH初剂TXA15 mg/kg,上限与速度核对儿科药品方案。以本院规范为准。Suspected bleeding with compromise: small initial resuscitation aliquots and early blood; RCH initial TXA 15 mg/kg, with maximum/rate checked in the pediatric product protocol. Follow institutional policy.
每份后复评;持续失血尽早血库/儿科MTP,不重复大量晶体液。Reassess each aliquot; ongoing hemorrhage needs blood-bank/pediatric MTP, avoiding repeated large crystalloids.
RCH:儿童重大创伤初评RCH: major pediatric trauma primary survey · WS/T 795—2022 儿科输血指南WS/T 795—2022 pediatric transfusion guideline
国内外依据与适用差异Domestic/international scope differences
国内重症失血性休克成分方案见下一卡;常规RBC 10–15表不适用于急救大出血。Chinese major-hemorrhage component regimen is on the next card; routine RBC table excludes emergency major bleeding.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
儿童:国内失血性休克输血索引Children: Chinese hemorrhagic transfusion index
RBC : FFP = 1 : 1(容量)以本院规范为准。RBC : FFP = 1 : 1 (volume) Follow institutional policy.WS/T795—2022 §9.5.2.2:儿童创伤性失血性休克。WS/T795—2022 §9.5.2.2: pediatric traumatic hemorrhagic shock.
标准举例RBC 20 mL/kg + FFP 20 mL/kg;不是常规贫血或非创伤比例。以本院规范为准。Standard example: RBC 20 mL/kg + FFP 20 mL/kg; not routine anemia/non-trauma ratio. Follow institutional policy.
RBC累计>40 mL/kg可考虑PLT15–20 mL/kg+冷沉淀10 mL/kg;按化验目标Hb>80、Fib>1.5、APTT/PT<中点1.5倍、PLT>75×10⁹/L调整并监测超负荷。以本院儿科方案为准。With cumulative RBC above40 mL/kg, consider platelets15–20 mL/kg and cryo10 mL/kg; adjust to Hb above80 g/L, Fib above1.5 g/L, APTT/PT below 1.5 times reference midpoint and PLT above75×10⁹/L; monitor overload. Follow institutional pediatric policy. Follow institutional policy.
WS/T 795—2022 儿科输血指南WS/T 795—2022 pediatric transfusion guideline · 儿科输血指南重症/大出血编制说明(2025)Chinese pediatric transfusion critical-bleeding interpretation (2025)
国内外依据与适用差异Domestic/international scope differences
此为成分容量方案示例,与RCH首轮小份的阶段不同;核对产品规格和本院儿童流程。A component-volume regimen, at a different stage from RCH initial aliquots; check product/local pediatric policy.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
烧伤:中国新九分法Burns: Chinese rule of nines
成人:9 + 18 + 27 + 46 = 100%以本院规范为准。Adult: 9 + 18 + 27 + 46 = 100% Follow institutional policy.头面颈、双上肢、躯干含会阴、双下肢含臀足。Head/face/neck; both arms; trunk including perineum; both legs including buttocks/feet.
12岁以下:头面颈=9+(12−年龄)%;双下肢=46−(12−年龄)%。以本院规范为准。Under 12: head/neck=9+(12−age)%; both legs=46−(12−age)%. Follow institutional policy.
静脉复苏评估:成人Ⅱ/Ⅲ度>15%、儿童>5%、老年>10%或Ⅲ度>5%;吸入伤与循环状态可独立升级。以本院规范为准。IV resuscitation assessment: adult partial/full-thickness over 15%, child over 5%, elder over 10% or full-thickness over 5%; inhalation injury/physiology may independently escalate. Follow institutional policy.
国家卫健委:突发事件烧伤伤员医疗救治规范(2025年版)NHC emergency burn treatment standard (2025 edition; published 2026)
国内外依据与适用差异Domestic/international scope differences
按2025版规范表1及§2.1;补液面积只计Ⅱ/Ⅲ度,不将Ⅰ度纳入。2025 standard Table 1 / §2.1; fluid-formula area uses second/third degree, excluding superficial burns.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
烧伤:国内成人补液公式Burns: Chinese adult fluid formula
首24 h:1.5–2 mL × kg × %TBSA + 2000 mL以本院规范为准。First 24 h: 1.5–2 mL × kg × %TBSA + 2000 mL Follow institutional policy.国内2025规范晶胶混合公式;Ⅱ/Ⅲ度,%填百分数数值。Chinese 2025 crystalloid/colloid formula; second/third degree; enter percentage number.
晶:胶=1–2:1;总估算量一半在伤后首8 h,余量分后两个8 h。以本院规范为准。Crystalloid:colloid=1–2:1; half estimated total in first eight hours from injury, quarters in next two intervals. Follow institutional policy.
尿量0.5–1 mL/(kg·h),电击/挤压/溶血性化学伤1–2;第二24 h晶胶减半、基础水分同首日;基础水分分配按烧伤科方案。以本院规范为准。Urine0.5–1 mL/(kg·h),1–2 for electrical/crush/hemolytic chemical injury; second-day crystalloid/colloid half first-day actual amount, maintenance unchanged; allocate maintenance per burn service. Follow institutional policy.
国家卫健委:突发事件烧伤伤员医疗救治规范(2025年版)NHC emergency burn treatment standard (2025 edition; published 2026)
国内外依据与适用差异Domestic/international scope differences
1.5是该版范围下限,不是唯一固定量;已输入液体计入总量,以本院烧伤流程为准。1.5 is the lower end, not a fixed universal amount; include prior fluids and follow local burn policy.
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing
儿童烧伤补液Pediatric burn fluids
首24 h:2 mL×kg×%TBSA(Ⅱ/Ⅲ度)+基础水分;以本院规范为准。First24 hours:2 mL×kg×%TBSA (partial/full thickness)+maintenance Follow institutional policy.儿童;基础水分70–100 mL/kg,<2岁100–150 mL/kgChildren; maintenance 70–100 mL/kg, under two years100–150 mL/kg
晶:胶1–3:1;1/2伤后首8 h,余量分后两个8 h;尿量约1 mL/(kg·h)。以本院烧伤规范为准。Crystalloid:colloid1–3:1; half in first eight hours from injury, remainder in the next two eight-hour periods; urine about 1 mL/(kg·h). Follow institutional burn policy. Follow institutional policy.
>5%可出现休克;头面颈伤警惕气道,按已输入量、循环和血糖动态调整。以本院规范为准。Over5% may cause shock; head/face/neck injury raises airway concern; adjust to previous fluids, circulation and glucose. Follow institutional policy.
国家卫健委:突发事件烧伤伤员医疗救治规范(2025年版)NHC emergency burn treatment standard (2025 edition; published 2026)
国内外依据与适用差异Domestic/international scope differences
不使用成人2000 mL基础水分;用实际体重和面积百分数数值Do not use adult 2000 mL maintenance; use actual weight and percentage-number area
来源核对日期:2026-10-14;临床审核:进行中Source check: 2026-10-14; clinical review: ongoing